There is more good news from leading stem cell biotech Advanced Cell Technology (ACT) on preclinical rodent studies using stem cells to treat mice with an MS-like condition.
They published a new paper in the journal Stem Cell Reports entitled “Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis” by Wang, et al.
Mesenchymal stem cells (MSCs) derived from human embryonic stem (hES) cells, termed hES-MSCs by the authors) were able to substantially reduce symptoms of a Multiple Sclerosis (MS)-like disease in mice.
Share this article
While the control mice were severely disabled by the MS modeling condition including paralysis, those treated with the hES-MSCs were significantly healthier. In some cases this difference was dramatic as shown in the video above (Courtesy of Dr. Xiaofang Wang and Dr. Ren-he Xu, ImStem Biotechnology, Inc.) where we see a hES-MSC-treated MS model mouse running around and a control severely ill.
Read the full, original story: Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS
